Combining a brain-signal booster and omega-3 for early dementia
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether combining a drug that boosts brain signaling (NMDA enhancement) with omega-3 supplements can improve memory and thinking in people with early dementia. It may offer a new way to slow down cognitive decline.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of Alzheimer's disease or mild cognitive impairment.
- Your score on a standard memory test (MMSE) is between 10 and 26.
- Your level of dementia, measured by the CDR scale, is 0.5 or 1.
- You do not have conditions like Parkinson's disease, epilepsy, severe depression, or a major physical illness.
- You have not taken memantine or special omega-3 supplements in the last 3 months.
- You do not have significant vision or hearing problems that would interfere with study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study looks at how well a medicine that targets DAO (an enzyme in the body) helps people with Alzheimer’s disease or mild cognitive impairment. You may be considered if your memory symptoms are mild to moderate and you meet specific brain-function and symptom scoring rules.
This trial tests whether taking B vitamins and omega-3 fatty acids can slow brain shrinkage in older adults. It may help those with low vitamin levels keep their memory sharp.
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
This trial tests a new combination treatment (DAOIB and an antioxidant) for people with early Alzheimer's or mild cognitive impairment. It aims to see if the treatment can help slow or improve memory and thinking problems.
This Phase 2 trial tests DAOIB to improve “brain fog” and thinking problems that happen after COVID-19. You may be screened if your symptoms started after a COVID infection and have lasted for months, and if your health tests are normal.
This study tests whether a DHA (omega-3) supplement can improve delivery of certain brain fats in older adults who have mild memory concerns. It involves taking a daily supplement and may include a lumbar puncture (spinal tap).
Hear when a new Fatty Acids, Omega-3 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.